Cellectis (NASDAQ:CLLS) Share Price Crosses Below Fifty Day Moving Average – Time to Sell?

Cellectis S.A. (NASDAQ:CLLS) shares crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $3.70 and traded as low as $3.59. Cellectis shares last traded at $3.63, with a volume of 29,099 shares.

Analyst Ratings Changes

A number of research firms have weighed in on CLLS. Barclays began coverage on Cellectis in a research report on Thursday. They issued an “overweight” rating and a $9.00 target price for the company. Citizens Jmp reiterated a “market outperform” rating and set a $8.00 price objective on shares of Cellectis in a research report on Tuesday, April 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellectis in a research report on Monday, April 20th. Finally, Jefferies Financial Group initiated coverage on Cellectis in a research report on Tuesday, February 17th. They set a “buy” rating and a $7.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Cellectis currently has an average rating of “Buy” and an average price target of $7.00.

Cellectis Price Performance

The business has a 50-day moving average price of $3.70 and a 200 day moving average price of $4.03. The company has a market cap of $353.20 million, a price-to-earnings ratio of -5.25 and a beta of 2.94. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 1.13.

Cellectis (NASDAQ:CLLS) last released its earnings results on Monday, May 11th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.08. The company had revenue of $7.55 million during the quarter, compared to analyst estimates of $11.04 million. Cellectis had a negative return on equity of 80.66% and a negative net margin of 89.51%.

Institutional Trading of Cellectis

A number of hedge funds have recently modified their holdings of the business. Lido Advisors LLC purchased a new stake in shares of Cellectis in the first quarter valued at $32,000. Marshall Wace LLP lifted its holdings in shares of Cellectis by 1,610.3% in the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after purchasing an additional 168,038 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Cellectis in the fourth quarter valued at $15,385,000. Global Retirement Partners LLC purchased a new stake in shares of Cellectis in the fourth quarter valued at $34,000. Finally, Millennium Management LLC lifted its holdings in shares of Cellectis by 61.9% in the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 22,080 shares in the last quarter. Hedge funds and other institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.